Refractory Langerhans cell histiocytosis Recruiting Phase 2 Trials for Tipifarnib (DB04960)

Indication	Status	Phase
DBCOND0022006 (Refractory Langerhans cell histiocytosis)	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03155620	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Screening	Ensartinib (DB14860) Erdafitinib (DB12147) Hydrogen (DB15127) LY-3023414 (DB12167) Larotrectinib (DB14723) Menthol (DB14123) Olaparib (DB09074) Palbociclib (DB09073) Selpercatinib (DB15685) Selumetinib (DB11689) Sulfate ion (DB14546) Tazemetostat (DB12887) Tipifarnib (DB04960) Ulixertinib (DB13930) Vemurafenib (DB08881) X-396 (DB13104)
NCT04284774	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Treatment	Tipifarnib (DB04960)